Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 - Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients
,
2021 – Sandoz, a global leader in biosimilar and generic medicines, today announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi
® (etanercept-szzs) for reference medicine Enbrel
® (etanercept). The Federal Circuit previously ruled against Sandoz in a divided decision upholding Amgen’s patents.
“We are disappointed the Supreme Court decided not to review our case,” said Keren Haruvi, President of Sandoz US and Head of North America. “Today’s decision means Erelzi, a more affordable biosimilar, will not be available to US patients with autoimmune and inflammatory diseases until 2029; nonetheless we remain committed to providing important treatment options for patients affected by these diseases.”